Association Between BNT162b2 and CoronaVac Vaccination and Risk of CVD and Mortality After COVID-19 Infection: A Population-based Cohort Study

Overview

Journal Cell Rep Med

Publisher Cell Press

Specialties Biology
General Medicine

Date 2023 Sep 16

PMID 37716352

Authors

Eric Yuk Fai Wan

Anna Hoi Ying Mok

Vincent Ka Chun Yan

Cheyenne I Ying Chan

Boyuan Wang

Francisco Tsz Tsun Lai

Celine Sze Ling Chui

Xue Li

Carlos King Ho Wong

Kai Hang Yiu

Hung Fat Tse

Chak Sing Lau

Ian Chi Kei Wong

Esther Wai Yin Chan

Affiliations

Soon will be listed here.

Abstract

It is unknown if vaccination affects the risk of post-COVID-19 cardiovascular diseases (CVDs). Therefore, this retrospective cohort study examines the short-term and long-term risks of post-infection CVD among COVID-19 patients with different vaccination status utilizing data from electronic health databases in Hong Kong. Cox proportional hazards regression adjusted with inverse probability of treatment weighting is used to evaluate the risks of incident CVD (coronary heart disease, stroke, heart failure) and all-cause mortality in COVID-19 patients. Compared with unvaccinated patients, vaccinated patients have a lower risk of CVD and all-cause mortality, and the lowest risk is observed in those who completed three doses of vaccine. Similar patterns in the subgroups of different vaccine platforms, age, gender, Charlson comorbidity index, and disease severity are observed. These findings highlight a positive dose-response relationship between overall CVD risk reduction and the number of vaccine doses received.

Citing Articles

Local adaptive immunity in atherosclerosis with T cell activation by aortic dendritic cells accelerates pathogenesis.

Zhang W, Cai Z, Ma D, Liu M, Wang J, Sun L iScience. 2024; 27(11):111144.

PMID: 39502289 PMC: 11536043. DOI: 10.1016/j.isci.2024.111144.

References

Koh S, Chen H, Hsu C . Prolonged peripheral seronegative spondyloarthritis following BioNTech coronavirus disease 2019 vaccination: A case report. Int J Rheum Dis. 2022; 26(4):774-777. DOI: 10.1111/1756-185X.14512. View

Mayr F, Talisa V, Castro A, Shaikh O, Omer S, Butt A . COVID-19 disease severity in US Veterans infected during Omicron and Delta variant predominant periods. Nat Commun. 2022; 13(1):3647. PMC: 9233663. DOI: 10.1038/s41467-022-31402-4. View

Levin E, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S . Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med. 2021; 385(24):e84. PMC: 8522797. DOI: 10.1056/NEJMoa2114583. View

Ruan Q, Yang K, Wang W, Jiang L, Song J . Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020; 46(5):846-848. PMC: 7080116. DOI: 10.1007/s00134-020-05991-x. View

Diaz-Arocutipa C, Saucedo-Chinchay J, Mamas M, Vicent L . Influenza vaccine improves cardiovascular outcomes in patients with coronary artery disease: A systematic review and meta-analysis. Travel Med Infect Dis. 2022; 47:102311. DOI: 10.1016/j.tmaid.2022.102311. View

Raman B, Bluemke D, Luscher T, Neubauer S . Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur Heart J. 2022; 43(11):1157-1172. PMC: 8903393. DOI: 10.1093/eurheartj/ehac031. View

Yan V, Wan E, Ye X, Mok A, Lai F, Chui C . Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case-control study. Emerg Microbes Infect. 2022; 11(1):2304-2314. PMC: 9553171. DOI: 10.1080/22221751.2022.2114854. View

Xie Y, Xu E, Bowe B, Al-Aly Z . Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022; 28(3):583-590. PMC: 8938267. DOI: 10.1038/s41591-022-01689-3. View

Abbasi J . The COVID Heart-One Year After SARS-CoV-2 Infection, Patients Have an Array of Increased Cardiovascular Risks. JAMA. 2022; 327(12):1113-1114. DOI: 10.1001/jama.2022.2411. View

10.

Patone M, Mei X, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M . Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2021; 28(2):410-422. PMC: 8863574. DOI: 10.1038/s41591-021-01630-0. View

11.

Cohen K, Ren S, Heath K, Dasmarinas M, Jubilo K, Guo Y . Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2022; 376:e068414. PMC: 8828141. DOI: 10.1136/bmj-2021-068414. View

12.

Daugherty S, Guo Y, Heath K, Dasmarinas M, Jubilo K, Samranvedhya J . Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2021; 373:n1098. PMC: 8132065. DOI: 10.1136/bmj.n1098. View

13.

Lauring A, Tenforde M, Chappell J, Gaglani M, Ginde A, McNeal T . Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022; 376:e069761. PMC: 8905308. DOI: 10.1136/bmj-2021-069761. View

14.

Cutler D . The Costs of Long COVID. JAMA Health Forum. 2022; 3(5):e221809. DOI: 10.1001/jamahealthforum.2022.1809. View

15.

Ranard L, Fried J, Abdalla M, Anstey D, Givens R, Kumaraiah D . Approach to Acute Cardiovascular Complications in COVID-19 Infection. Circ Heart Fail. 2020; 13(7):e007220. PMC: 8126417. DOI: 10.1161/CIRCHEARTFAILURE.120.007220. View

16.

Tartof S, Slezak J, Fischer H, Hong V, Ackerson B, Ranasinghe O . Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021; 398(10309):1407-1416. PMC: 8489881. DOI: 10.1016/S0140-6736(21)02183-8. View

17.

Mohamed M, Banerjee A . Long COVID and cardiovascular disease: a learning health system approach. Nat Rev Cardiol. 2022; 19(5):287-288. PMC: 8943785. DOI: 10.1038/s41569-022-00697-7. View

18.

Feikin D, Higdon M, Abu-Raddad L, Andrews N, Araos R, Goldberg Y . Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022; 399(10328):924-944. PMC: 8863502. DOI: 10.1016/S0140-6736(22)00152-0. View

19.

Abu-Raddad L, Chemaitelly H, Butt A . Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med. 2021; 385(2):187-189. PMC: 8117967. DOI: 10.1056/NEJMc2104974. View

20.

Wan E, Mok A, Yan V, Wang B, Zhang R, Hong S . Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: A case control study. J Infect. 2022; 85(5):e140-e144. PMC: 9381942. DOI: 10.1016/j.jinf.2022.08.008. View